Send us Fan Mail

In this episode of Veteran Cancer Talk, Ashton speaks with Dr. Elizabeth O’Donnell, Director of the Multicancer Early Detection Clinic at the Dana-Farber Cancer Institute, about one of the most promising developments in oncology: multicancer early detection (MSED) testing.

MSED tests use a single blood draw to analyze DNA methylation signatures that may indicate the presence of cancer. Some commercially available tests can screen for up to 50 different types of cancer — including many that currently have no recommended screening options.

Dr. O’Donnell explains:

• How MSED testing works
• Why these tests complement — not replace — traditional screenings
• The Sentinel Study evaluating MSED in veterans
• Eligibility requirements for participation
• What happens after an abnormal result
• Current limitations and false positive rates
• The future of early cancer detection and Medicare reimbursement

This conversation explores how emerging blood-based screening tools could reshape cancer detection — particularly for veterans who may face elevated cancer risks due to service-related exposures.

To learn more about the Sentinel Study or Veteran Cancer Network, visit:
www.veterancancernetwork.org or https://www.sentinelstudy.com/

Support the show

Veteran Cancer Network is building the resource we wish we had. Connecting veterans and caregivers navigating cancer.

Learn more at www.veterancancernetwork.org